Molecular Pharmacology (USA), Net Tangible Assets

As of the most recent data (September 2014), MLPH shows a net tangible assets of $-2.1M. That compares with $-2.1M in the prior-year period — up 1.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MLPH's net tangible assets is now $-2.1M (was $-2.1M) — a 1.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Molecular Pharmacology (USA), is outperforming or lagging.

Tracking MLPH's net tangible assets over time shows whether Molecular Pharmacology (USA), is scaling, shrinking, or reshaping that part of the business. The current reading is $-2.1M That compares with $-2.1M in the prior-year period — up 1.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has Molecular Pharmacology (USA),'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $-2.1M) with ownership activity and broader fundamentals.